Table 3

Univariate analysis of 30-day outcome of ICH among patients with hematological malignancies.

Alive (n = 26)

Dead (n = 46)

Univariate analysis, P value

Multivariate analysis, P value (odds ratio; 95% CI)


Gender:

0.604

Male

16

32

Female

10

14

Age

>0.999

≥60 years

12

20

<60 years

14

26

Hematological malignancies

0.679

AML

14

29

APL

5

4

ALL

2

3

Lymphoma

3

4

Myeloma

2

6

Remission status

0.448

Yes

4

4

No

22

42

Post HSCT

0.473

Yes

2

7

No

24

39

Underlying hypertension

>0.999

Yes

7

12

No

19

34

Sepsis

0.050

Yes

8

26

No

18

20

CNS involvement

>0.999

Yes

2

4

No

24

42

Subarachnoid hemorrhage

0.007

0.021 (10.9; 1.3 to 88.9)

Yes

1

14

No

25

32

Multifocal hemorrhage

0.006

0.026 (4.7; 1.6 to 14.0)

Yes

6

27

No

20

19

Surgical intervention

0.085

Yes

7

4

No

19

41

Leukocyte count

>0.999

≥100,000 cells/μl

4

8

<100,000 cells/μl

22

38

Platelet count

0.802

≥20,000 cells/μl

16

30

<20,000 cells/μl

10

16

Prolongation of prothrombin time

0.013

0.008 (10.9; 1.3 to 85.5)

INR ≥1.5

1

14

INR <1.5

24

32


ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; CNS = central nervous system; HSCT = hematopoietic stem cell transplantation; ICH = intracranial hemorrhage; INR = international normalized ratio.

Chen et al. BMC Medicine 2012 10:97   doi:10.1186/1741-7015-10-97

Open Data